Buy & Sell iShares MSCI Taiwan ETF (EWT) – iShares MSCI Taiwan ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -10.51%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 54% Buy | 46% SellTrading Activity
- 8 daysTypical Hold Time
Over the past 52 weeks, iShares MSCI Taiwan ETF has traded between a low of $52.38 and a high of $97.15, highlighting its annual price range. Over the past three months, iShares MSCI Taiwan ETF has recorded a drawdown of -10.51%, reflecting recent price volatility. On average, investors hold iShares MSCI Taiwan ETF for approximately 8 days, indicating typical investor behavior on the platform.
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Most Recent News
Futurionex upgrades AI Quant 2.0 with high-frequency execution to boost trading speed and efficiency.
Futurionex has enhanced its AI Quant 2.0 platform by integrating high-frequency execution capabilities, improving the speed and efficiency of converting trading strategy signals into actual trades. This upgrade addresses the critical need for rapid o...

Futurionex upgrades AI Quant 2.0 to boost high-frequency trading efficiency amid rising crypto volatility
Futurionex Blockchain Trading Ltd. has launched an update to its AI Quant 2.0 system, enhancing high-frequency trading execution to improve efficiency from strategy signals to order completion. This upgrade allows faster data capture and order execut...

Novartis unveils new data advancing prostate, breast cancer and hematology treatments at ASCO and EHA 2026.
Novartis presented over 65 abstracts at the 2026 ASCO and EHA meetings, highlighting new data on its radioligand therapy Pluvicto for prostate cancer, Kisqali for breast cancer, and Scemblix for chronic myeloid leukemia. The data reinforce Novartis' ...
